| Source: |
| Type: |
| Snail gene may show a role in recurrence of breast cancer by downregulating E-cadherin and inducing an epithelial to mesenchymal transition. Snail promotes metastasis of breast cancer cells and overexpression of Snail is a biomarker of poor clinical outcome for patients with breast cancer. Snail, a repressor of E-cadherin and an inducer of EMT. Snail (SNAI1): A transcription factor that plays a key role in the regulation of the epithelial-to-mesenchymal transition (EMT). It suppresses the expression of epithelial markers (such as E-cadherin) and upregulates mesenchymal markers, facilitating changes in cell adhesion and motility. EMT Induction: Snail actively represses genes such as E-cadherin, a protein critical for cell–cell adhesion. Its upregulation leads to a loss of epithelial characteristics and the acquisition of a mesenchymal phenotype, enhancing migratory potential. Invasion and Metastasis: Through EMT induction, Snail facilitates tumor cell dissemination and invasion into surrounding tissues, thereby playing a central role in metastasis. Elevated levels of Snail have been observed in a variety of cancers, including breast, colorectal, pancreatic, and head and neck cancers. Elevated Snail expression is frequently associated with a worse prognosis, including lower overall survival rates and increased likelihood of metastasis. |
| Breast Cancer |
| 1333- | AG, | Astragalus polysaccharide inhibits breast cancer cell migration and invasion by regulating epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway |
| - | in-vitro, | BC, | NA |
| 1106- | CGA, | Chlorogenic Acid Inhibits Epithelial-Mesenchymal Transition and Invasion of Breast Cancer by Down-Regulating LRP6 |
| - | vitro+vivo, | BC, | MCF-7 |
| - | in-vitro, | BC, | NA |
| 2880- | HNK, | Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | BC, | BT549 |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | SUM159 |
| 1236- | PTS, | Pterostilbene inhibits the metastasis of TNBC via suppression of β-catenin-mediated epithelial to mesenchymal transition and stemness |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 4699- | PTS, | Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vivo, | BC, | MDA-MB-231 |
| 65- | QC, | Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB |
| - | in-vitro, | BC, | NA |
| 3092- | RES, | Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MCF-7 |
| 4900- | Sal, | Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications |
| - | Review, | BC, | NA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | MCF12A | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:4 Cells:% prod#:% Target#:376 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid